MIB-1 Labeling Index is Very Important Proliferative Factor for Lymphangioma  

Yoko Kishi M.D., Ph.D1* and Kentaro Matsuoka M.D., Ph.D2*

Dokkyomedical university Saitama medical center, 2-1-50, Minamikoshigaya Koshigayashi Saitama, 〒343-8555, Japan.

2Tokyo Metropolitan Children’s Medical Center, Japan.

*Correspondence:  
Yoko Kishi M.D., Ph.D, Dokkyo Medical University, Saitama Medical Center, 2-1-50, Minamikoshigaya Koshigayashi Saitama, Japan, Tel;81-48-965-1111, Fax:81-48-965-1134.

Kentaro Matsuoka M.D., Ph.D, Tokyo Metropolitan Children’s Medical Center, Japan.

Received: 01 March 2021; Accepted: 20 March 2021

Citation: Kishi Y, Matsuoka K. MIB-1 Labeling Index is Very Important Proliferative Factor for Lymphangioma. J Med - Clin Res & Rev. 2021; 5(4): 1-5.

ABSTRACT

Our concept for the treatment of lymphangioma is simple resection if it is small and adjacent to the surface of the skin and intralobular injection of OK-432 if it is big. Resection of the mass is performed if its size has reduced after observation, but persisted. The rapid growth of the lymphangioma has been considered to be due to inflammation and invasion of the vessels, but their relationship remains unclear. Our hypothesis is that the Mib1-labeling index of endothelial cells of fast-growing lymphangioma is larger than that of non-proliferating lymphangioma. Mib-1 labeling index shows their ability of proliferation.

In our study, we could show the high potential cells of lymphangioma had high MIB1 index using the immunological technique of the pathology.

Keywords
Lymphangioma, MIB1-index, proliferative factor.

Introduction
Lymphangioma is an irreversible disease that could recur after the lymphoma has been resected. Our concept for the treatment of lymphoma is simple resection if it is small and adjacent to the surface of the skin and intralobular injection of OK-432 if it is big. Resection of the mass is performed if its size has reduced after observation, but persisted. The rapid growth of the lymphoma has been considered to be due to inflammation and invasion of the vessels, but their relationship remains unclear. Our hypothesis is that lymphangioma which grows rapidly and recurs easily has a higher mib-1 labeling index value compared to lymphangioma that does not recur at all.

The mib1-labeling index is an important indicator of proliferative ability in lymphangioma. In our study, we compared with the cases which exist in a surface of the skin has no recurrence and those which treated many times and aimed for studying a difference between them for the cell ability by protein related endothelium of the lymphoma using the immunological technique of the pathology.

Materials and Methods
A total of 104 cases of lymphangioma from 1996 to 2018 were enrolled in the study, where 44 patients were treated surgically. Of them, 16 patients were included for analysis. We investigated age, sex, a part, the treatment of the patient, histopathological views. The pathological search performed H-E stein; CD31(JC70A, DAKO x60), as the marker of the vascular endothelium [1]; CD34(QBEnd10, DAKO x200), as the positive reaction for the malignant tumor of the lymph duct [2]; D2-40 (Bioss antibodies, x300), as the maker of the lymphangioma [3]. VGEFR-3 (Bioss antibodies, x300), as an evaluation of the lymphatic duct [4]; PROX-1 (EPR19273, ABCAM, x200), as the instruction from the blood vessel to the lymphatic endothelia [5], and Ki-67 (Atlas antibodies 50x9) as a marker for cell proliferation that labeled except G0 period [6].
Results
All cases were classified according to the common microcystic lymphatic malformation type, based on the ISSVA 2018 guidelines. The patients were divided into two groups: the resection only (group A) and the post-OK-432 injection (group B) groups. The median age of operation in group A was 5.8 years (range: 1 to 16 years) and 2 months to 2 years old, an average of 11 months median of 6 months to 1 year old; median age in group B was lower than in group A.

Both groups were mainly consisted of boys. Lymphangioma was seen in the face, neck, trunk, and extremities of group A, but only in the trunk and extremities in group B. Group A consisted of 6 cases, and group B consisted of 6; OK-432 was injected one to three times and operative time ranged from 1 to 3 hours (average: 1.9 hours) in group A, and from 1 to 4 hours (average: 1.83 hours) in group B (Table 1). Histopathological findings were observed in all cases, showing many cavities, which all looked like thin, expanded lymphatic, which were lined by a single layer of endothelial cells. Immunohistochemical staining methods using CD31, CD34, D2-40, PROX1, VEGFR3, and Ki-67 were applied for both groups. All cases were classified according to the common microcystic lymphatic malformation type, based on the ISSVA 2018 guidelines.

Table 1: Cases.

| Case | Age/Sex | OP | HE fibrosis | Cyst size | PROX1 | D2-40 | CD31 | CD34 |
|------|---------|----|-------------|-----------|--------|-------|------|------|
| OK432(+)1 | 1.3/M | 1st | Big small | + | + | + | + |
| 2.3 | 2nd | - | - | + | + | + | - |
| 2 | 1.3/F | 1st | - | - | + | + | - |
| 2 | 2nd | - | - | + | + | - | + |
| 3 | 2.6/F | 1st | - | - | + | - | + |
| 2nd | - | - | - | + | - | - | - |
| 4 | 1.8/M | 1st | - | - | + | - | - |
| 5 | 1/F | 1st | - | - | + | + | - |
| 6 | 0.6/M | 1st | - | - | + | - | - |
| 2nd | - | - | - | + | + | - | - |
| 3rd | - | - | - | + | + | - | - |
| 4th | - | - | - | + | + | - | - |
| OK432(-)1 | 4/M | nd | - | + | + | + | - |
| 2 | 17/M | nd | - | + | + | + | - |
| 3 | 3/F | nd | - | + | + | + | - |
| 4 | 5/M | nd | - | + | + | + | - |
| 5 | 3/F | nd | - | + | + | + | - |
| 6 | 2.9/M | nd | - | + | + | + | - |

Discussion
Lymphatic vessel and development of lymphangiomas
There are two major theories on the proliferation of lymphatic capillaries; one is the centripetal theory by Huntington [7] which suggested that lymphatic endothelium fused each other, then became lymphatic cyst, and lymphatic duct formed the vascular system along the veins and opened to the vein secondly, the other theory was centrifugal theory which Sabin et.al [8] suggested that the lymphatic endothelium which sprouted from the vein developed in the lymphatic network distally. Huntington’s theory has been in the limelight recently, since the lymphatic endothelium, which did not originate from the vascular endothelium was found, and a different mechanism controlled both the origin and development between the neck and trunk; therefore, the endothelium which formed the collecting duct came from the lymphatic cyst of the neck. The endothelium of the heart was made both from vascular and non-vascular endothelia, using non-vein-derived stem cells. Conversely, it is thought that lymphangiomas is derive from remnants of five primitive lymphatic cysts (bilateral neck,
Table 2: MIB1 labeling index.

| Case   | Ok432  | Size     | MIB1 positive cells | Average | MIB1 index | Recurrence |
|--------|--------|----------|---------------------|---------|------------|------------|
| 1      | +      | Small    | 0/19                | 0/20    | 0/24       | 0/15       | 0/36       | 0/22.8     | 0          | —          |
| 2      | +      | small-big| 0/13                | 0/93    | 0/85       | 0/256      | 0/22       | 0/93.8     | 0          | —          |
| 2      | +      | Middle destruction | 0/19 | 0/62 | 0/40.5 | 0 | — |
| 3      | +      | Small    | 0/14                | 0/16    | 0/26       | 0/21       | 0/60       | 0/27.6     | 0          | —          |
| 4      | +      | Middle destruction | 0 | 0 | 0 | 0 | — |
| 5      | +      | Middle    | 4/96                | 0/82    | 1/30       | 1/98       | 2/82       | 1.6/77.6   | 2%         | +          |
| 5      | +      | Small Middle destruction | 1/24 | 1/22 | 3/83 | 1/29 | 3/37 | 1.8/39 | 4.6% | Repid Growth+ |
| 5      | +      | Middle destruction | 1/92 | 2/88 | 1/90 | 4/59 | 1/39 | 1.8/73.6 | 2.45% | — |
| 6      | +      | Small    | 3/45                | 1/35    | 2/14       | 0/20       | 1/27       | 1.4/28.2   | 4.96%      | —          |
| 7      | —      | Small-big | 2/212 | 1/33 | 2/27 | 1/10 | 1/17 | 1.4/59.8 | 2.34% | — |
| 8      | —      | Big      | 3/252               | 2/240   | 2/14       | 0/20       | 1/27       | 1.4/28.2   | 4.96%      | —          |
| 9      | —      | Big      | 18/1180             | 5/531   | 2/240      | 2/14       | 0/20       | 1/27       | 1.4/28.2   | 4.96%      | —          |
| 10     | —      | Small-big | 1/113 | 1/76 | 2/36 | 0/37 | 0/47 | 1.6/61.8 | 2.59% | — |
| 11     | —      | Very small | 0/19 | 0/10 | 0/60 | 0/7 | 0/105 | 0/38.2 | 0 | — |
| 12     | —      | Big      | 20/119              | 3/132   | 8/210      | 3/172      | 1/84       | 7/143.4    | 4.88%      | +          |

Figure 1: Group A.

PROX1 was all positive and D2-40 is a part negative in the lymphatic endothelial cells. CD34 was negative.
Figure 2: Group B (small cyst).
CD-34 was negative in small cystic lymphatic lumen.

Figure 3: Group B (big cyst).
D2-40 CD34 PROX1 were positive in large cysts and the granulation tissue.

Figure 4: Group B (second operation).
PROX1 was positive in the part which jumped out to the vessel wall.

Figure 5: Ki-67.
Preparations of PROX-1 and Ki-67 stain were continued to the one of H-E stain.

Acquired lymphangiogenesis is different from congenital lymphangiogenesis with respect to the point of sprouting, which is formed from existing lymphatic vessels so that it may differentiate into leaf and a macrophage, converging into a lymph duct. In various inflammation and tissue repair processes, it is reported that VEGF-C, which increases vascularization, and VEGFR3 (which is the receptor of VEGF-C) increased the number of lymphatic vessels. The driving force of lymphangiogenesis is said to be guided by macrophage and VEGF-C, intervened by a thromboxane receptor of the T lymphocytes. Lymphangioma is considered a chronic inflammation without the awareness, since the granulation tissue was observed as pathological findings in group A. Many small ducts were observed around the big duct of the lymphangioma, but whether these small ones would converge into the big duct or not remains unknown, since no inflammation was found in the small duct. During surgery, we sometimes observed lymph fluid leaking from the small lymphatic vessels; it was hard to see, even though the branch of big lymph vessels were ligated. We cannot exclude the possibility of promotion to change to large lymphatic vessels by secretion of VEGF-C and prostaglandin. It was shown that the possibility of connection between the small and big lymphangiomas was poor, since the cyst wall of the small lymphangioma did not involve any inflammation, but inflammation occurred in the cyst wall of the big lymphangioma, after the injection of OK-432. The causes which had several treatments showed the lymphangiogenic power in the scar; PROX1 expression was positive, indicating lymphangiogenesis.

Effectiveness of the treatment methods
The normal superficial lymphatic vessel does not accomplish with any vessels, goes through the subcutaneous adipose tissue,
arrives at the regional lymph node in a subcutaneous adipose tissue without the blood vessel. From the surgeons’ point of view, it is required to perform complete resection of adipose tissue around the lymph vessel if the lymph vessel in the adipose tissue which cannot be macroscopically observed participates in the recurrence of lymphangioma; our result showed that additional resection of tissue around the lymphangioma was not required; connection between the small and big lymphangiomas was poorer than what we had imagined. A new question is: “how do we determine the possibility of sudden growth of the lymphangioma?” CD34 was reported by Dick in 1997 that there is the stem cell of the malignant tumor and the malignant tumor had positive in CD34.

**Rapid growth of the lymphangioma**

CD34

Our results showed the positive response of the big duct of lymphangioma and the recurrence rate. We believe that the reason for treatment of a lymphangioma with a high recurrence rate, even though the operation counted several times is difficult, since the cell potential looks the similarity of metastasis of the malignant tumor [9]. Therefore, CD34 is an important index for the potential growth of the lymphangioma.

**Ki-67 and MIB-1 labeling index**

Cells that are positive for Ki-67 show the intensity of cell activity. In-group B, especially in the cases where only a small cavity remained after the first operation, but the cysts grew. The second operation revealed the destruction of the lymphatic endothelium; It was found that OK-432 was destructive for the lymphatic endothelium; Ki-67 positive cells were removed by OK-432, so recurrence was not observed. In-group A, the big cavity was major, and there were numerous Ki-67 positive cells. This explains why the recurrence rate was low, since all most Ki-67 positive cells were completely removed during surgery. From the result of group A, group B was imagined basically the size of cavity should be big. Yamamoto [10] has classified lymphangioma into two groups; microcystic (where the duct measures under 1 cm) and macrocystic (where it measures over 1 cm); furthermore, it was classified in two types, MLC (large cyst, with a diameter of over 2 cm) and MSC (small cyst, with a diameter of under 5 mm). The LM-MIB index score for the microcystic type was high; MSC had the highest score. Our study could not show the differences of the intensity of cell activity was popular in the small cavity. In one case, injection of OK-432 did not destroy it enough; the middle-sized cyst and Ki-67 positive cells persisted after 3 resection attempts; positive reaction rate decreased and additional resection was not required.

Many reports state the Mib-1 labeling index shows the proliferation of malignant tumors. Yamamoto et.al [11] also showed that Ki67 positive cell was an important factor to show the effectiveness of R-CHOP method in follicular lymphoma. Absolutely, lymphangioma is not malignant, but some of them characterized by rapid cell proliferation. We can’t explain only The MIB-labeling index is a very important proliferative factor for lymphangioma as same as malignant tumors.

**Acknowledgment**

We would like to thank Editage (www.editage.com) for English language editing.

**References**

1. Sen Hong. ATAD2 silencing decrease VEGFA secretion through targeting hasmiR-520a to inhibit angiogenesis in colorectal cancer. Biochem Cell Biol. 2018; 96: 761-768.
2. Traweek ST, Kandalaft PL, Mehta P, et al. The human hematopoietic progeny cell antigen CD34 in vascular neoplasms. Am J Clin Pathol. 1991; 96: 25-311.
3. Kalof AN, Cooper K. D2-40 immunohistochemistry-so far. Adv Anat Pathol. 2009; 16: 62-64.
4. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004; 5: 74-80.
5. Mishima K, Watabe T, Saito A, et al. Prox-1 induces lymphatic endothelial differentiation via integrin alpha-9 and other signaling cascades. Mol Biol Cell. 2007; 18: 1421-1429.
6. Brown DC, Gatter KC. Monoclonal antibody Ki-67 in histopathology. Histopathology. 1990; 17: 489-503.
7. Huntington GC, McClure CFW. The anatomy and development of the jugular lymph sacs in the domestic cat Felis domestica. Am J Anat. 1910; 10: 177-311.
8. Sabin FR. On the origin of the lymphatic system from the veins and the development of the lymph hearts and thoracic duct in the pig. Am J Anat. 1902; 1: 367-389.
9. Dick JE. Assey of human stem cells by repopulation of NOD/SCID mice. Stem Cells. 1997; 15: 199-203.
10. Yamamoto M, Watanabe S, Abe Y, et al. Analysis of proliferation and differentiation activity of Lymphatic endothelial cells in lymphangioma. Showa J. 2009; 174-180.
11. Yamamoto E, Tomita N, Sakata S, et al. MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated rituximab plus CHOP therapy. Cancer Sci. 2013; 104: 1670-1674.